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Background
Biomarker-based personalized treatment has improved
the prognosis of many tumors. EGFR, KRAS, and BRAF
mutations and EGFR antibody treatment (colorectal car-
cinoma) and EGFR inhibitor treatment (lung carcinoma)
serve as good examples. The rapid improvement of bio-
marker-based treatments requires that not merely one
biomarker but many biomarkers such as mutations, gene
fusion, and gene copy number alterations, are to be
tested simultaneously for selection of the ideal combina-
tion of molecularly targeted and individual treatment.
Next-generation sequencing (NGS) makes it possible to
study mutations, gene fusions, and copy numbers genome
wide in one single analysis. This presentation based on
our three papers [1-3] in press illustrates the feasibility,
even superiority of NGS for biomarker analysis in human
neoplasias.
Aims
1) As EGFR, KRAS, and BRAF mutations are clinically
relevant, mainly predictive biomarkers in colorectal and
lung carcinomas, we aimed to evaluate by NGS and routi-
nely used real-time PCR (RT-PCR) methods the feasibility
of NGS for analysis of these mutations. Furthermore, we
aimed, by NGS, to reveal novel mutations.
2) Anaplastic lymphoma kinase (ALK) gene fusions
occur in a small proportion of non-small cell lung carci-
nomas. Identification of the fusions is crucial for targeted
treatment decisions. We aimed to screen ALK gene
fusions in lung carcinomas, and to compare the results
that were studied by NGS with those detected by routine
methods, including standard fluorescence in situ -hybri-
dization (FISH), immunohistochemistry (IHC), and
RT-PCR. We conducted the ALK fusion analyses on 95
formalin-fixed paraffin-embedded (FFPE) tumor tissues
from 87 patients with non-small cell lung carcinoma.
3) In many human neoplasias such as acute lymphoblas-
tic leukemia, chromosomal deletions at 9p are common.
To study the feasibility of NGS for detection of copy num-
ber alterations at chromosome 9p, we conducted NGS
and array-comparative genomic hybridization (aCGH)
analyses on 35 patients with acute lymphoblastic leukemia.
Methods
Methods for NGS, aCGH, FISH, RT-PCR, and IHC appear
in the original articles [1-3]. Our NGS method was based
on targeted resequencing. For EGFR, KRAS, BRAF, and
ALK, all the exons (for ALK and also some intronic areas)
were sequenced. For 9p, target regions were sequenced
with a total length of 1 Mb from a 32 Mb region. For cap-
ture of target regions, baits were custom-designed to cap-
ture all exons.
Results and discussion
Comparison of NGS and PCR methods for detection of
EGFR, KRAS, and BRAF mutations in lung carcinoma [1]
We observed a significant concordance (from 96.3 to
100%) of the EGFR, KRAS, and BRAF mutation detection
results between targeted NGS and RT-PCR. Moreover,
targeted NGS revealed seven non-synonymous single-
nucleotide variations and one insertion-deletion variation
in EGFR undetectable by the real-time PCR methods. The
potential clinical significance of these variants requires
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elucidation in future studies. Our results support the use
of targeted NGS in the screening of EGFR, KRAS, and
BRAF mutations in FFPE tissue material.
Detection of ALK fusions in lung carcinoma by NGS, FISH,
RT-PCR, and ICH [2]
All methods were successful on FFPE tumor tissue mate-
rial. Of the 87 patients examined, we detected ALK fusion
in 5 (5.7%). Results from resequencing correlated signifi-
cantly with those from FISH, RT-PCR, and IHC. Targeted
NGS proved a promising method for ALK gene fusion
detection in non-small-cell lung carcinomas. Means to
reduce the material and turnaround time required for ana-
lysis are, however, necessary.
NGS as a method for detection of copy number
alterations [3]
In detection of copy number alterations at 9p, high con-
cordance occurred between NGS and aCGH. Both meth-
ods revealed deletions at the CDKN2A/B locus, whereas
NGS revealed additional small deletions outside the reso-
lution of aCGH. Furthermore, NGS showed mutations
and gene fusions impossible to see by aCGH. To conclude,
novel copy number alterations, mutations, and structural
alterations were revealed.
Conclusions
For two reasons, NGS was superior for biomarker analysis:
the possibility to see a large range of gene mutations in
one analysis, and the possibility to detect mutations, gene
fusions, and copy number alterations simultaneously in a
single test. Our studies illustrated the feasibility of NGS
for clinical specimens of FFPE tumors .We also showed
that in addition to mutations, gene fusions and copy num-
ber alterations can also be reliably detected by NGS. As
the costs and required material for NGS analyses has
decreased to near that of PCR or FISH, NGS may very
soon become a method to replace all other methods for
biomarker analyses of human malignancies.
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